Preservation of lean mass during GLP-1-mediated weight loss is a clinically meaningful outcome in primary care, where patients on these agents often have baseline sarcopenia, reduced functional capacity, or comorbid conditions that increase fall and fracture risk. If differential lean mass preservation is confirmed between agents, family medicine clinicians will need to incorporate body composition considerations alongside glycemic and weight targets when selecting between tirzepatide and semaglutide. This is particularly relevant for older adults, patients with osteoporosis, and those undergoing significant caloric restriction, where skeletal muscle loss carries direct implications for long-term morbidity and independence.

A recent study comparing GLP-1 and dual GIP/GLP-1 receptor agonists evaluated body composition changes associated with semaglutide and tirzepatide, with particular attention to the proportion of weight loss attributable to lean mass versus fat mass. While tirzepatide has been established in prior trials as producing greater absolute weight loss than semaglutide, this analysis examined whether that advantage comes with a differential impact on skeletal muscle and lean tissue preservation, a clinically meaningful distinction given the role of muscle mass in metabolic health, functional capacity, and long-term weight maintenance.

The key finding was that semaglutide was associated with less lean mass loss relative to total weight lost compared to tirzepatide. In practical terms, patients on tirzepatide lost more total weight, but a greater portion of that loss included lean mass, whereas semaglutide-treated patients preserved a relatively higher proportion of lean tissue during the weight loss process. Specific compositional data from the study indicated that the lean mass loss as a percentage of total weight lost was meaningfully higher with tirzepatide, raising questions relevant to prescribers managing patients with sarcopenic obesity, older adults, or individuals for whom muscle preservation is a priority alongside fat reduction.

For prescribers, these findings introduce a nuanced consideration into agent selection. Tirzepatide remains the more potent option for total weight reduction, which carries its own cardiometabolic and glycemic benefits. However, clinicians treating patients where lean mass preservation is a primary concern, such as those with low baseline muscle mass, physical function limitations, or elevated fall risk, may weigh these body composition data alongside total efficacy outcomes. Concurrent resistance training and adequate protein intake remain important adjuncts regardless of agent, and individualized decision-making should account for the full clinical picture rather than weight loss magnitude alone.

Emerging comparative data suggest that certain GLP-1 receptor agonists may differ meaningfully in their effects on body composition, particularly in how much lean muscle mass is preserved during weight loss treatment. While tirzepatide tends to produce greater overall weight reduction than semaglutide, this new research indicates that semaglutide may offer a relative advantage in preserving lean mass, which is an important consideration beyond the scale number alone. Preserving muscle during weight loss is clinically significant because lean mass supports metabolic rate, functional strength, and long-term weight maintenance. When counseling patients on GLP-1 therapy, family medicine clinicians should proactively discuss the importance of adequate protein intake and resistance exercise alongside medication, framing body composition preservation as a core treatment goal rather than a secondary concern.

“The emerging data on lean mass preservation with semaglutide versus tirzepatide is clinically meaningful and deserves more attention than it typically gets in headline-level coverage. While tirzepatide does produce greater total weight loss, the composition of that weight matters enormously, particularly for older patients and those with sarcopenia risk where preserving muscle mass is as important as losing fat. In my practice, this is exactly the kind of nuance I bring to shared decision-making conversations, because a patient who loses more weight but sacrifices more muscle may actually end up metabolically worse off in the long run. When counseling patients on agent selection, I now routinely frame the choice not just around how much weight they will lose, but around what kind of weight they will lose.”

? Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

Have thoughts on this? Share it: